Merck Serono Japan Launches Colon Cancer Drug Erbitux
This article was originally published in PharmAsia News
Executive Summary
Merck KGaA Japanese subsidiary Merck Serono Japan launched colon cancer drug Erbitux (cetuximab) Sept. 19. The company is marketing the drug under a joint promotion agreement with Bristol-Myers Squibb. The drug is indicated to treat progressive and relapsing colon cancers. As Japanese diets are increasingly westernized, colon cancers cases are on the rise. (Click here for more - Japanese language